Q2 2021 Alligator Bioscience AB Earnings Call Transcript
Hello, and welcome to the Alligator Bioscience Q2 report 2021. (Operator Instructions)
Today, I'm pleased to present CEO, Søren Bregenholt; and CFO, Marie Svensson. Please go ahead with your meeting, sir.
¸ -
Yeah. Thank you. Thank you and welcome to this Q2 report call. If we go to the slide, slide number 2, our forward-looking statement. So in slide 3, I'll take you through the significant events in Q2. Most importantly, we at the ASCO meeting on June 4, presented the new encouraging data from our 4-1BB agonistic antibody, ATOR-1017, showing solid proof of mechanism data combined with strong safety data, really giving us a strong belief in the potential of this second-generation 4-1BB agonist in immuno-oncology.
We also recently presented preclinical collaboration data. Our preclinical data from our collaboration with Scandion Oncology, combining our CD40 agonist, mitazalimab with chemotherapy and the Scandion agent in chemo-resistant tumors. From Alligator's point of view, the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
